调查研究
Gao Wenbin;Wang Lishuang;Wang Lei;Wang Huaijin;Yin Liangwei
2003, 5(3): 156-159.
Objective:To investigate the blood toxicity of topotecan and evaluate its safety in clinical practice.Method:113cases with non-small cell lung cancer were divided into three treatment groups:53cases in TP group(topotecan0.75mg per m 2 body-surface and cisplatin20mg per m 2 on days1to5),30cases in NP group(vinorelbine25mg per m 2 on day1and day8,and cisplatin20mg per m 2 on days1to5),30cases in HP group(hydroxycamptothecine6mg per m 2 and cisplatin20mg per m 2 on days1to5).3courses(a course of21days)were given,then the blood toxicity was assessed.Results:The efficacy rate of TP group was39.62%,NP group33.33%and HP group30.00%,with no significant differences between them(P>0.05).As for blood toxicity in TP group,third degree and fourth degree leucopenia occured in18and15cases respectively,accounting for62.26%,and third degree and four th degree thrombocytopenia in15and13cas-es respectively,accounting for52.83%.Compared with NP and HP groups,both leucopenia and thrombocytopenia in TP group showed significant differences(P<0.05).Conclusion:Blood counts should be made frequently because white blood cells and platelets would be seriously affected by topotecan,resulting in leucopenia and thrombocytopenia.
